On May 26, 2023, Sun Pharmaceutical proposed via a letter to Taro’s Board of Directors a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the company or its affiliates, for a purchase price of $38 per share, in cash.
| Subscribe To Our Free Newsletter |
